BiotechTube

Avelumab

Phase 3Terminated
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

POLE Exonuclease Mutant Colon Cancer

Conditions

POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer

Trial Timeline

Aug 31, 2018 → Jan 5, 2022

NCT ID
NCT03827044

About Avelumab

Avelumab is a phase 3 stage product being developed by Merck for POLE Exonuclease Mutant Colon Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03827044. Target conditions include POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer.

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT03089658Pre-clinicalCompleted
NCT06412848Pre-clinicalActive
NCT05600127Phase 2Recruiting
NCT05431777Pre-clinicalCompleted
NCT05366725Pre-clinicalCompleted
NCT04822350Pre-clinicalCompleted
NCT03815643Phase 3Active
NCT03514719Phase 1Completed
NCT03568097Phase 2UNKNOWN
NCT03827044Phase 3Terminated
NCT03674424Phase 2Completed
NCT03439501Phase 2UNKNOWN
NCT03147404Phase 2Completed
NCT03352934Phase 2Completed
NCT03389126Phase 2Completed
NCT03278379Phase 2Completed
NCT03278405Phase 1/2Completed
NCT03403777Phase 2Completed
NCT03491345Phase 2UNKNOWN
NCT03244176Phase 1Active